$APVO
Aptevo Therapeutics Inc.

2022 Q4 Form 10-Q Financial Statement

#000156459022037287 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $3.096M
YoY Change -100.0% -100.0% 112.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.010M $3.307M $3.479M
YoY Change -4.81% -4.94% 8.04%
% of Gross Profit
Research & Development $4.674M $4.477M $4.367M
YoY Change 2.88% 2.52% -2.74%
% of Gross Profit
Depreciation & Amortization $161.0K $222.0K $296.0K
YoY Change -38.08% -25.0% -1.33%
% of Gross Profit
Operating Expenses $7.684M $4.477M $7.846M
YoY Change -0.27% -42.94% 1.76%
Operating Profit -$7.784M -$4.750M
YoY Change 63.87%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.521M -$25.00K -$2.327M
YoY Change -198.59% -98.93% 232.43%
Pretax Income -$5.163M -$7.809M -$7.077M
YoY Change -21.74% 10.34% 1.83%
Income Tax
% Of Pretax Income
Net Earnings -$4.642M -$7.644M -$6.997M
YoY Change -25.99% 9.25% 3.03%
Net Earnings / Revenue -226.0%
Basic Earnings Per Share -$1.50 -$1.43
Diluted Earnings Per Share -$0.86 -$1.50 -$1.430M
COMMON SHARES
Basic Shares Outstanding 5.092M 5.091M 4.892M
Diluted Shares Outstanding 5.091M 4.892M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.64M $22.15M $52.12M
YoY Change -49.75% -57.5% 109.31%
Cash & Equivalents $22.64M $22.15M $53.38M
Short-Term Investments
Other Short-Term Assets $744.0K $658.0K $3.659M
YoY Change -4.62% -82.02% -14.91%
Inventory
Prepaid Expenses $1.571M $1.383M
Receivables $2.500M $0.00 $3.096M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $27.45M $24.62M $58.87M
YoY Change -47.78% -58.18% 91.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.462M $1.669M $4.386M
YoY Change -38.55% -61.95% -26.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $746.0K
YoY Change -100.0% -100.0% -6.75%
Total Long-Term Assets $6.765M $7.077M $5.132M
YoY Change 67.82% 37.9% -23.4%
TOTAL ASSETS
Total Short-Term Assets $27.45M $24.62M $58.87M
Total Long-Term Assets $6.765M $7.077M $5.132M
Total Assets $34.22M $31.70M $64.00M
YoY Change -39.55% -50.48% 71.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.499M $3.243M $3.687M
YoY Change 1.07% -12.04% -5.46%
Accrued Expenses $2.505M $7.572M $3.104M
YoY Change -19.09% 143.94% 19.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $11.17M
YoY Change -82.86% -82.09%
Total Short-Term Liabilities $8.706M $7.786M $32.38M
YoY Change -74.95% -75.95% 337.57%
LONG-TERM LIABILITIES
Long-Term Debt $1.456M $1.910M $4.012M
YoY Change -60.72% -52.39% -84.08%
Other Long-Term Liabilities $6.079M $6.237M $20.32M
YoY Change -64.07% -69.31% 681.58%
Total Long-Term Liabilities $1.456M $1.910M $24.33M
YoY Change -92.94% -92.15% -12.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.706M $7.786M $32.38M
Total Long-Term Liabilities $1.456M $1.910M $24.33M
Total Liabilities $16.24M $15.93M $56.71M
YoY Change -70.68% -71.91% 61.12%
SHAREHOLDERS EQUITY
Retained Earnings -$206.0M -$201.4M
YoY Change -3.75%
Common Stock $224.0M $217.2M
YoY Change 4.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.97M $15.76M $7.292M
YoY Change
Total Liabilities & Shareholders Equity $34.22M $31.70M $64.00M
YoY Change -39.55% -50.48% 71.14%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$4.642M -$7.644M -$6.997M
YoY Change -25.99% 9.25% 3.03%
Depreciation, Depletion And Amortization $161.0K $222.0K $296.0K
YoY Change -38.08% -25.0% -1.33%
Cash From Operating Activities -$5.939M -$6.896M -$5.242M
YoY Change 53.07% 31.55% -29.07%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$4.000K -$13.00K
YoY Change -100.0% -69.23%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$4.000K -$13.00K
YoY Change -100.0% -69.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.998M -500.0K -3.021M
YoY Change -294.99% -83.45% -112.22%
NET CHANGE
Cash From Operating Activities -5.939M -6.896M -5.242M
Cash From Investing Activities 0.000 -4.000K -13.00K
Cash From Financing Activities 5.998M -500.0K -3.021M
Net Change In Cash 59.00K -7.400M -8.276M
YoY Change -100.83% -10.58% -147.73%
FREE CASH FLOW
Cash From Operating Activities -$5.939M -$6.896M -$5.242M
Capital Expenditures $0.00 -$4.000K -$13.00K
Free Cash Flow -$5.939M -$6.892M -$5.229M
YoY Change 57.87% 31.8% -29.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11667000
dei Entity Registrant Name
EntityRegistrantName
APTEVO THERAPEUTICS INC.
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34757000
CY2021Q4 apvo Liabilities Held For Sale Non Current
LiabilitiesHeldForSaleNonCurrent
15580000
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei City Area Code
CityAreaCode
206
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
APVO
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1383000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4898143
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56601000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3096000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13208000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3307000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3479000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7784000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
658000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1669000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5408000
CY2021Q4 us-gaap Assets
Assets
56601000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2327000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4048000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3462000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
37182000
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
80000
us-gaap Net Income Loss
NetIncomeLoss
-22185000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.80
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4891881
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5017684
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4617357
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
727000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17799000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
595000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-595000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10550000
apvo Repayments Under Liability Related To Sale Of Royalties
RepaymentsUnderLiabilityRelatedToSaleOfRoyalties
5531000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10233000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6237000
CY2022Q3 us-gaap Liabilities
Liabilities
15933000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
47000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
217109000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-201394000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15762000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1372000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2077000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1171000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7786000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5090644
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5090644
dei Entity Central Index Key
EntityCentralIndexKey
0001671584
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1341000
CY2021Q4 us-gaap Liabilities
Liabilities
55385000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
215232000
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98121
dei Local Phone Number
LocalPhoneNumber
838-0500
dei Entity File Number
EntityFileNumber
001-37746
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1567056
dei Entity Address Address Line1
EntityAddressAddressLine1
2401 4th Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5091758
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22150000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45044000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
427000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1259000
CY2021Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
3664000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1823000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
780000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
52570000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2379000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1584000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1216000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214063000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
492000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
626000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10863000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5451000
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7077000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
12177000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-22811000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7644000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6997000
us-gaap Net Income Loss
NetIncomeLoss
12669000
us-gaap Profit Loss
ProfitLoss
12669000
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3114000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8627000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4367000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11536000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4750000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20957000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17360000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
857000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1383000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1695000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
-524000
apvo Increase Decrease In Long Term Operating Lease Liability
IncreaseDecreaseInLongTermOperatingLeaseLiability
750000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5884000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10843000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42534000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22577000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53377000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31695000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-630000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15083000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
11767000
apvo Repayments Under Liability Related To Sale Of Royalties
RepaymentsUnderLiabilityRelatedToSaleOfRoyalties
6779000
CY2019Q1 apvo Pre Funded Warrants And Rights Outstanding Term
PreFundedWarrantsAndRightsOutstandingTerm
P10Y
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 us-gaap Assets Current
AssetsCurrent
24618000
CY2022Q3 us-gaap Assets
Assets
31695000
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3243000
CY2021Q4 apvo Liabilities Held For Sale Current
LiabilitiesHeldForSaleCurrent
15465000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2086000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1910000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3707000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4898143
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4477000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14451000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7809000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
165000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5090592
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5090592
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4891881
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5019552
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4617357
us-gaap Profit Loss
ProfitLoss
-22185000
us-gaap Share Based Compensation
ShareBasedCompensation
1445000
us-gaap Share Based Compensation
ShareBasedCompensation
1465000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
740000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
888000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
3262000
apvo Non Cash Interest Expense And Other
NonCashInterestExpenseAndOther
4387000
apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
apvo Increase Decrease In Royalties Receivable
IncreaseDecreaseInRoyaltiesReceivable
-3664000
apvo Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
548000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
apvo Proceeds From Sale Of Royalties
ProceedsFromSaleOfRoyalties
35000000
apvo Transaction Costs From Sale Of Royalties
TransactionCostsFromSaleOfRoyalties
1100000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
apvo Value Of Equity Awards Withheld For Tax Liability
ValueOfEquityAwardsWithheldForTaxLiability
4000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
985000
apvo Proceeds From Milestones Related To Sale Of Royalties
ProceedsFromMilestonesRelatedToSaleOfRoyalties
10000000
apvo Transaction Costs For Milestones Related To Sale Of Royalties
TransactionCostsForMilestonesRelatedToSaleOfRoyalties
500000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
436000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8614000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29237000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23726000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46303000
apvo Change In Rou Asset And Lease Liability From Lease Remeasurement
ChangeInROUAssetAndLeaseLiabilityFromLeaseRemeasurement
4372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1216000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-4000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
601000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7697000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
436000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
485000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
28010000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23047000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
359000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7644000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15762000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16594000
CY2021Q1 apvo Proceeds From Exercise Of Stock Options Value
ProceedsFromExerciseOfStockOptionsValue
-86000
CY2021Q1 apvo Proceeds From Exercise Of Warrants Value
ProceedsFromExerciseOfWarrantsValue
-506000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
574000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7256000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
10504000
CY2021Q2 apvo Proceeds From Exercise Of Stock Options Value
ProceedsFromExerciseOfStockOptionsValue
-25000
CY2021Q2 apvo Proceeds From Exercise Of Warrants Value
ProceedsFromExerciseOfWarrantsValue
-478000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10234000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
572000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7932000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
13881000
CY2021Q3 apvo Proceeds From Exercise Of Stock Options Value
ProceedsFromExerciseOfStockOptionsValue
-89000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
319000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6997000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
7292000
CY2022Q3 apvo Number Of Technology Platforms
NumberOfTechnologyPlatforms
2
apvo Non Cash Interest Expense
NonCashInterestExpense
3416000
apvo Non Cash Interest Expense
NonCashInterestExpense
3709000
us-gaap Payments For Royalties
PaymentsForRoyalties
6779000
us-gaap Payments For Royalties
PaymentsForRoyalties
5529000
apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37182000
CY2021Q3 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
32080000
apvo Liability Related To Sale Of Royalties Current
LiabilityRelatedToSaleOfRoyaltiesCurrent
-13369000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the unaudited condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, forecasted royalties, effective interest rates, clinical accruals, useful lives of equipment, commitments and contingencies, and stock-based compensation. Given the continuing global economic and geopolitical climate and effects from the ongoing COVID-19 pandemic, these estimates are becoming more challenging, and actual results could differ materially from those estimates.</p>
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000
CY2022Q1 apvo Milestone Payment
MilestonePayment
10000000
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
apvo Liability Related To Sale Of Royalties Non Current
LiabilityRelatedToSaleOfRoyaltiesNonCurrent
18711000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4400000
CY2022Q3 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
165000
CY2021Q3 apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
80000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
492000
apvo Disposal Group Including Discontinued Operations Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue
399000
apvo Discontinued Operating Gain On Contingent Consideration
DiscontinuedOperatingGainOnContingentConsideration
227000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
165000
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
80000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
492000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
626000
CY2022Q2 apvo Deferred Payments Increase Percentage
DeferredPaymentsIncreasePercentage
0.02
CY2022Q2 apvo Deferred Payments Increase Percentage
DeferredPaymentsIncreasePercentage
0.05
CY2020Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000.0
CY2021Q1 apvo Payment Of Amount Outstanding
PaymentOfAmountOutstanding
10000000.0
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5000000.0
CY2022Q3 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
600000
CY2021Q3 apvo Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
100000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4400000
apvo Operating Lease Property Number Of Copiers
OperatingLeasePropertyNumberOfCopiers
4
apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
apvo Finance Lease Number Of Equipment
FinanceLeaseNumberOfEquipment
1
CY2022Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18400000
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
41200000
apvo Cash Equivalents Maturity Period
CashEquivalentsMaturityPeriod
P90D
CY2022Q3 us-gaap Cash
Cash
3731000
CY2021Q4 us-gaap Cash
Cash
3841000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18419000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
41203000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
427000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22577000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46303000
CY2021Q1 apvo Amendment Fees
AmendmentFees
600000
CY2021Q1 apvo Proceeds From Sale Of Investments
ProceedsFromSaleOfInvestments
35000000.0
CY2022Q1 apvo Milestone Payment
MilestonePayment
10000000.0
CY2022Q2 apvo Gain On Extinguishment Of Liability Related To Sale Of Royalties
GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties
37200000
CY2022Q2 apvo Payment Of Royalty Revenue Percentage
PaymentOfRoyaltyRevenuePercentage
0.50
CY2022Q2 apvo Payment Of Royalty Purchase Agreement Percentage
PaymentOfRoyaltyPurchaseAgreementPercentage
1.90
CY2021Q4 apvo Liability Related To Sale Of Royalties
LiabilityRelatedToSaleOfRoyalties
31045000
us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
33900000
apvo Milestone Payment Received Net Of Transaction Costs
MilestonePaymentReceivedNetOfTransactionCosts
9500000
CY2021Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2022Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
299000
us-gaap Operating Lease Cost
OperatingLeaseCost
978000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
395000
us-gaap Operating Lease Cost
OperatingLeaseCost
1185000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
5000
CY2022Q3 us-gaap Lease Cost
LeaseCost
299000
us-gaap Lease Cost
LeaseCost
980000
CY2021Q3 us-gaap Lease Cost
LeaseCost
397000
us-gaap Lease Cost
LeaseCost
1190000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4617357
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5090592
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4891881
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5408000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1584000
us-gaap Operating Lease Payments
OperatingLeasePayments
779000
us-gaap Operating Lease Payments
OperatingLeasePayments
1053000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6200000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1203
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1446
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7809000
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7077000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
12177000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-22811000
CY2022Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
165000
CY2021Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
80000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
492000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
626000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7644000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6997000
us-gaap Net Income Loss
NetIncomeLoss
12669000
us-gaap Net Income Loss
NetIncomeLoss
-22185000
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.53
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.45
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.42
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.94
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.53
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.45
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.42
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.94
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.03
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.10
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.14
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.03
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.10
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.14
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5090592
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4891881
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5017684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5019552
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4617357
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
359000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
319000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1444000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1464000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.60
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1600000
CY2019Q1 apvo Prefunded Warrant Expiration Date
PrefundedWarrantExpirationDate
2029-03-11

Files In Submission

Name View Source Status
apvo-20220930_lab.xml Edgar Link unprocessable
0001564590-22-037287-index-headers.html Edgar Link pending
0001564590-22-037287-index.html Edgar Link pending
0001564590-22-037287.txt Edgar Link pending
0001564590-22-037287-xbrl.zip Edgar Link pending
apvo-10q_20220930.htm Edgar Link pending
apvo-20220930.xsd Edgar Link pending
apvo-20220930_cal.xml Edgar Link unprocessable
apvo-10q_20220930_htm.xml Edgar Link completed
apvo-ex101_33.htm Edgar Link pending
apvo-ex311_12.htm Edgar Link pending
apvo-ex312_6.htm Edgar Link pending
apvo-ex31_124.htm Edgar Link pending
apvo-ex321_9.htm Edgar Link pending
apvo-ex322_11.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
apvo-20220930_def.xml Edgar Link unprocessable
apvo-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending